S100B and neoplasm: Dasatinib-treated mice maintained ERα status and reduced primary tumor expression of p-Src kinase, the co-activator SRC-1, the transcription factor HOXC11, and their target gene S100β (Fig. 5b, Additional file 1: Figure S5).